Bays, Harold E.

Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study

Moriarty, P. M., Roth, E. M., Karns, A., Ye, P., Zhao, S.-P., Liao, Y., Capuzzi, D. M., Bays, H. E., Zhang, F., Liu, S., et al. (2014) · Journal of clinical lipidology

Lipoproteins and Cardiovascular HealthNatural Products and Biological Research

Cited by 65

Nutrition and physical activity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022

Alexander, L., Christensen, S. M., Richardson, L., Ingersoll, A. B., Burridge, K., Golden, A., Karjoo, S., Cortez, D., Shelver, M., & Bays, H. E. (2022) · Obesity Pillars

Diet and metabolism studiesObesity, Physical Activity, Diet

Cited by 61

Effects of Prescription Omega-3-Acid Ethyl Esters on Non—High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin

Bays, H. E., McKenney, J., Maki, K. C., Doyle, R. T., Carter, R. N., & Stein, E. (2010) · Mayo Clinic Proceedings

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 54

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Philip, S., Doyle, R. T., Braeckman, R. A., Stirtan, W. G., Soni, P. N., & Juliano, R. A. (2016) · Atherosclerosis

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 52

Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects

Davidson, M. H., Bays, H. E., Stein, E., Maki, K. C., Shalwitz, R. A., & Doyle, R. (2006) · Clinical Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 51

Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects

Bays, H., Pi-Sunyer, X., Hemmingsson, J. U., Claudius, B., Jensen, C. B., & Van Gaal, L. (2017) · Current Medical Research and Opinion

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 48

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies

Ballantyne, C. M., Bays, H. E., Braeckman, R. A., Philip, S., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2016) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 47

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 46

Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies

Bays, H. E., Ballantyne, C. M., Doyle, R. T., Juliano, R. A., & Philip, S. (2016) · Prostaglandins & Other Lipid Mediators

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 43

Licogliflozin, a novel SGLT1 and 2 inhibitor: body weight effects in a randomized trial in adults with overweight or obesity

Bays, H. E., Kozlovski, P., Shao, Q., Proot, P., & Keefe, D. (2020) · Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 41

Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease

Bays, H. E. (2009) · Expert Review of Cardiovascular Therapy

Pharmacology and Obesity TreatmentAdipokines, Inflammation, and Metabolic Diseases

Cited by 39

Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk

Bays, H., Rodbard, H. W., Schorr, A. B., & González-Campoy, J. M. (2007) · Current Treatment Options in Cardiovascular Medicine

Cardiovascular Disease and AdiposityAdipokines, Inflammation, and Metabolic Diseases

Cited by 36

Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Bays, H. E., Golden, A., & Tondt, J. (2022) · Obesity Pillars

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 34

Prescription Omega-3 Fatty Acid as an Adjunct to Fenofibrate Therapy in Hypertriglyceridemic Subjects

Roth, E. M., Bays, H. E., Forker, A. D., Maki, K. C., Carter, R., Doyle, R. T., & Stein, E. A. (2009) · Journal of Cardiovascular Pharmacology

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 32

What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?

Bays, H. E., & Ballantyne, C. (2009) · Current Opinion in Lipidology

Lipoproteins and Cardiovascular HealthFolate and B Vitamins Research

Cited by 29

Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development

Bays, H. E. (2011) · Expert Review of Cardiovascular Therapy

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 28

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins

Bays, H. E., Baum, S. J., Brinton, E. A., Plutzky, J., Hanselman, J. C., Teng, R., & Ballantyne, C. M. (2021) · American Journal of Preventive Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 25

Comprehensive care for patients with obesity: An Obesity Medicine Association Position Statement

Fitch, A., Alexander, L., Brown, C. F., & Bays, H. E. (2023) · Obesity Pillars

Obesity and Health PracticesObesity, Physical Activity, Diet

Cited by 24

Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial

Mamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H. (2025) · European Heart Journal Open

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 24

Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies

Catapano, A. L., Mikhailova, E., Navar, A. M., Banka, P., Corral, P., Saxena, M., Steg, P. G., Verma, S., Kordahi, A. Y., Mendizabal, G., et al. (2026) · JACC

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 19

Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs)

Bays, H. E., Burridge, K., Richards, J., & Fitch, A. (2022) · Obesity Pillars

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 18

Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions

Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 14

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)

Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · Diabetologie und Stoffwechsel

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 13